Organizing pneumonia as a side effect of ipilimumab treatment of melanoma
IZ Barjaktarevic, N Qadir, A Suri, JT Santamauro… - Chest, 2013 - Elsevier
Ipilimumab is one of the newly developed human monoclonal antibodies used in the
treatment of metastatic melanoma. Its primary mechanism of action is a specific blockade of
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a T-cell receptor responsible for
inhibition of lymphocyte activation. By blocking CTLA-4, ipilimumab enhances immune
responses against tumor cells, but also exposes normal tissues to an increased risk of
autoimmune phenomena as a potential side effect. In this report, we describe the case of a …
treatment of metastatic melanoma. Its primary mechanism of action is a specific blockade of
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a T-cell receptor responsible for
inhibition of lymphocyte activation. By blocking CTLA-4, ipilimumab enhances immune
responses against tumor cells, but also exposes normal tissues to an increased risk of
autoimmune phenomena as a potential side effect. In this report, we describe the case of a …